Amish N. Raval

4 weeks ago | healio.com | Regina Schaffer |Richard Smith |Mary Walsh |Amish N. Raval

Key takeaways: Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an investigational cell therapy. A new trial will commence for patients with HFrEF and elevated NT-proBNP. CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its primary efficacy outcome.